R-Pharm Group

is one of the leaders of the Russian pharmaceutical market
Группа компаний «Р-Фарм» – один из лидеров инновационных технологий здоровья

R-Pharm specializes in research and development, manufacturing of high-tech medicines, as well as the distribution of laboratory supplies and medical equipment. Various Russian leading medical institutions and organizations are among the clients of the group.

The staff consists of more than 3,000 highly qualified professionals. There are more than 70 branches and representative offices. R-Pharm’s headquarters are located in Moscow.
Группа компаний «Р-Фарм» – Исследования и разработки
News from R-Pharm

The Ministry of Health of the Russian Federation has allowed simultaneous vaccination against coronavirus infection and influenza. The corresponding changes were made to the instructions for the medical use of […]

The post The Ministry of Health has allowed simultaneous vaccination against coronavirus and influenza appeared first on GxP News.

According to the instructions for the Sputnik V coronavirus vaccine published in the State Register of Medicines (GRLS), breastfeeding is no longer a contraindication for vaccination with the drug. That […]

The post The Ministry of Health approved vaccination of nursing mothers with Sputnik V appeared first on GxP News.

The Expert Council of the Industrial Development Fund approved a loan for Nanolek on Priority Projects program, according to the press center of the IDF. Nanolek, which is based in […]

The post Nanolek localizes production of active pharmaceutical substituents of HPV vaccine appeared first on GxP News.

AO Valenta Pharm pharmaceutical company is ready to provide a two-week course to all patients with multiple sclerosis (MS) who have indications for Kinesia® (Fampridine) and have a prescription for […]

The post Valenta Pharm announced the launch of its Early Access Program for the use of Kinesia® appeared first on GxP News.

St. Petersburg Research Institute of Influenza named after A.A. Smorodintsev named its COVID-19 vaccine in the form of nasal drops Corfluvec. This was announced during the St. Petersburg International Health Forum by Darya […]

The post The coronavirus vaccine created at the Research Institute of Influenza was named Corfluvec appeared first on GxP News.

The company actively carries out charitable work, supports educational, social, cultural, sport and health projects, implements training programs and conducts internships for talented Russian students and young scientists.